You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY22 is not expected to be complete until September, 2023.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
-
TFEB Activator for Alzheimer's Disease Therapy
SBC: BRILLIANT BIOSCIENCES INC. Topic: NIAOne in ten of the persons ageare affected by Alzheimer s diseaseADcausing enormous social and economic burden to the United StatesTo date only five medications have been approved by the FDA for the treatment of the symptoms of ADbut none of them slows or stops the disease progressionWith the recent repeated failures of AD drugs on thesecretase inhibitorsthe need for an effective AD drug became eve ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
3D Holographic Guidance, Navigation, and Control (3D GN&C) for Endovascular Aortic Repair (EVAR)
SBC: Centerline Biomedical, Inc. Topic: NHLBIProject Summary This project will develop newD visualization to improve stent graft deployment during minimally invasive endovascular aortic repairEVARby overcoming limitations ofD x ray fluoroscopyfluoroD holographic guidancenavigation and controlD GNandamp Cwill be provided to decrease fluoro radiation dose burden to patients and OR staff during treatment of aortic aneurysmsparticularly when dep ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Enhancing Clinical Therapy for wet Age-related Macular Degeneration (wetAMD)
SBC: NANOHYBRIDS INC Topic: NABSTRACTThe wet form of age related macular degenerationAMDaccounts forof all AMD related blindness and affectsmillion people withnew cases each year in the USMinimally invasive and selective drug delivery to the eye still remains an open challengethe current standard of care involves delivery of antivascular endothelial growth factoranti VEGFdrugs via intraocular injectionFor patients refractory ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Veristride STEP-R: an interactive verbal/auditory gait trainer
SBC: Veristride, Inc. Topic: 600Veristride IncProject Summary When surveyedof stroke survivors said the ability toget out and aboutis considered between important and essential for a better lifeHoweverthat desire falls short of reality for most stroke survivorsOftenwalking across a neighborhood street or from a car to a home is an insurmountable task with little opportunity for working on improvement in gaitOnce insurance covera ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Testing and Commercialization of a Superior Device to Maintain Perioperative Normothermia In Anesthetized Patients
SBC: Mercury Biomed LLC Topic: 300Project SummaryAbstractThis proposal presents Phase II of Mercury Biomedandapos s plan for commercializing the new and innovative WarmSmart technology to more effectively keep surgical patients normothermicWarmSmart embodies several breakthrough concepts in bioheat transfer to manage core temperatureWe are building a costcompetitive patient warming technology that will be superior to existing tech ...
STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
Novel Immuno-oncology Strategy for Targeted Cytotoxic Lymphocyte Activation
SBC: Courier Therapeutics Inc Topic: 102PROJECT SUMMARY ABSTRACT Systemic administration of high dose ILhas been used since thes as an FDA approved immunotherapy for metastatic cancerDespite the fact that up toof patients treated with high dose ILachieve a durablelong term responsethis therapy is rarely used today due to significant life threatening complicationsSuch complications occur due to ILactivation of vascular endotheliumresulti ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Overcoming anti-PD-1 resistance by systemic delivery of an oncolytic adenovirus that targets TGF-beta
SBC: Multivir Inc. Topic: 102Project Summary The overall goal of this proposal is to test a novel systemic Adenoviral therapy that targets transforming growth factorTGFand reverses anti PDresistance to treat advanced breast and lung cancersThis STTR grant application illustrates the synergistic relationship between DrPrem Sethinventor of a novel TGFdecoyand MultiVir Inca leader in clinical development of gene based therapeuti ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Technology for the non-invasive surveilance of post-traumatic compartment syndrome
SBC: Myolex Inc Topic: NIAMSPROJECT SUMMARYAcute compartment syndromeACSremains one of the most devastating and often overlooked traumatic musculoskeletal disorders in clinical practiceIn this conditionpressure increases in one of the body s spacelimited compartmentsdue most commonly to direct trauma or bone fractureresulting ultimately in an ischemic injury to all of the compartment s contentsincluding muscle and nerveOnce ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Small Molecule Inhibitor Therapeutic Target for Alzheimer's Disease.
SBC: abSynapTex, LLC Topic: NIAProject SummaryThe objective of our proposed research is to develop a water soluble molecule that can reduce the levels of amyloid betaAand Drpand prevent abnormal interactions between Aand Drpin Alzheimers diseaseADaffected neuronsOur previous AD studies foundincreased production and accumulation of Aand increased expression of Drpandan abnormal interaction between Aand Drpin AD neurons that was ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Create Ultralong DNA Constructs in One Assembly Step
SBC: FIREBIRD BIOMOLECULAR SCIENCES LLC Topic: 400Create Ultralong DNA Constructs in One Assembly Step Firebird Biomolecular Sciences LLCSteven ABenner Foundation for Applied Molecular EvolutionShuichi Hoshika AbstractFrost andampSullivan found aglobal market for DNA oligos at $million$million for genesPrivate investment in DNA synthesis companies like TwistGinkgoand DNA Script give collective valuations of several billion dollarsFederal public i ...
STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health